Abstract
Current approved medical therapies for endometriosis rely on drugs that suppress ovarian steroids and induce a hypoestrogenic state, which determines the atrophy of the ectopic endometrium. Gonadotropin-releasing hormone analogs such as danazol, progestogens and estrogen-progestin combinations have all proven effective in relieving pain and reducing the extent of endometriotic implants. However, symptoms often recur after discontinuation of therapy and hypoestrogenism-related side effects limit the long-term use of most medications. Recently, knowledge of the pathogenesis of endometriosis, particularly at the molecular level, has grown substantially, providing a rational basis for the development of new drugs with precise targets that may be safely administered over the long term. © 2006 Future Medicine Ltd.
Author supplied keywords
Cite
CITATION STYLE
Fedele, L., Blanchi, S., Fontana, E., Berlanda, N., Frontino, G., & Bulfoni, A. (2006, March). Medical management of endometriosis. Women’s Health. https://doi.org/10.2217/17455057.2.2.297
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.